Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 10/20 | 0.58 |
| ▸ | MEN1 | O00255 | 7/20 | 0.58 |
| ▸ | MLYCD | O95822 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3060224 | 0.90 | MLYCD (0.50) | KMT2AMEN1MLYCDNPC1RAB9A | |
| SCHEMBL9639949 | 0.83 | KMT2A (0.56) | KMT2AMEN1MLYCDKDM4EHTT | |
| SCHEMBL9292204 | 0.82 | KMT2A (0.57) | KMT2AMEN1HTTNPC1RAB9A | |
| SCHEMBL3941842 | 0.81 | PPIB (0.52) | KMT2AMEN1MLYCDKDM4ESMN1; SMN2 | |
| SCHEMBL5696786 | 0.81 | MLYCD (0.69) | KMT2AMEN1MLYCDKDM4EHTT | |
| SCHEMBL8568846 | 0.81 | KMT2A (0.63) | KMT2AMEN1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL22048518 | 0.81 | KMT2A (0.49) | KMT2AMEN1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL970622 | 0.81 | HPGD (0.49) | KMT2AMEN1MLYCDKDM4ESMN1; SMN2 | |
| SCHEMBL13074834 | 0.80 | GRM5 (0.44) | KMT2AMEN1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL1760632 | 0.79 | KMT2A (0.58) | KMT2AMEN1HTTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121625-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | Glaxo Group Limited (GB) | 2009-11-25 | — | — | EP | claimed |
| WO-2008092879-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | claimed |
| US-10729703-B2 | Withaferin compositions for prevention of aging | INSILICO MEDICINE IP LIMITED (HK) | 2020-08-04 | — | — | US | disclosed |
| US-20180125865-A1 | WITHAFERIN COMPOSITIONS FOR PREVENTION OF AGING | INSILICO MEDICINE IP LIMITED (HK) | 2018-05-10 | — | — | US | disclosed |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERISTY | 2018-03-29 | — | — | US | disclosed |
| US-8980874-B2 | Method and composition for treating diabetic ketoacidosis | MIDWESTERN UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-08-29 | — | — | US | disclosed |
| US-8410148-B2 | Method and composition for potentiating an opiate analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120070513-A1 | Method and Composition for Treating Diabetic Ketoacidosis | GULATI ANIL (US) | 2012-03-22 | — | — | US | disclosed |
| US-7973064-B2 | Administering to a mammal therapeutically effective amount of opiate analgesic and endothelin antagonist for therapy and prophylaxis of pain | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100311665-A1 | Method and Composition for Potentiating an Opiate Analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100184725-A1 | Method and Composition for Treating Alzheimer's Disease and Dementias of Vascular Origin | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100173872-A1 | Method and Composition for Treating Alzheimer's Disease and Dementias of Vascular Origin | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-07-08 | — | — | US | disclosed |
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | WYETH (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080207763-A1 | Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic | UNIVERSITY OF ILLINOIS CHICAGO (US) | 2008-08-28 | — | — | US | disclosed |
| US-7351692-B2 | Method and composition for potentiating the antipyretic action of a nonopioid analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070513-A1 | Method and Composition for Treating Diabetic Ketoacidosis | EDNRB, EGLN3, BDKRB2 | KMT2A 3313/4885MEN1 3268/4885MLYCD 344/4885 |
| US-20100184725-A1 | Method and Composition for Treating Alzheimer's Disease and Dementias of Vascular Origin | PSEN1, PSEN2, CHAT | KMT2A 3240/4885MEN1 1564/4885MLYCD 4116/4885 |
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | MMP8, MMP26, MMP9 | KMT2A 4052/4885MEN1 2254/4885MLYCD 3403/4885 |
| US-20080207763-A1 | Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic | COX15, PTGER3, PTGER4 | KMT2A 4769/4885MEN1 1456/4885MLYCD 2018/4885 |
| US-20100173872-A1 | Method and Composition for Treating Alzheimer's Disease and Dementias of Vascular Origin | PSEN1, PSEN2, CHAT | KMT2A 3240/4885MEN1 1564/4885MLYCD 4116/4885 |
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | PSEN1, PSEN2, CHAT | KMT2A 3240/4885MEN1 1564/4885MLYCD 4116/4885 |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | ADRB3, ADRA2A, ADRB2 | KMT2A 2749/4885MEN1 4170/4885MLYCD 3212/4885 |
| US-20100311665-A1 | Method and Composition for Potentiating an Opiate Analgesic | OPRK1, OPRL1, OPRM1 | KMT2A 4264/4885MEN1 4455/4885MLYCD 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.